Real-time enrollment status for this metastatic castration resistant prostate cancer clinical trial
Current Status
Recruiting
Checked: October 18, 2026 at 6:46 AM UTC
| NCT Number | NCT07723248 |
| Recruiting Status | Recruiting |
| Condition | Metastatic Castration Resistant Prostate Cancer |
| Phase | PHASE3 |
| Target Enrollment | 600 participants |
| Active Locations | 11 sites in the US |
| Sponsor | ORIC Pharmaceuticals |
| Last Updated on CT.gov | October 5, 2026 (1 week ago) |
As of October 18, 2026: Clinical trial NCT07723248 is currently recruiting participants. This phase3 study for metastatic castration resistant prostate cancer is actively seeking new participants at 11 locations across the United States. The study is sponsored by ORIC Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07723248 is actively recruiting participants as of October 18, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 11 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07723248 was last updated 1 week ago (October 5, 2026). HelloStudys verifies this status automatically.